Matching drugs trial for relapsed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have peripheral T-cell lymphoma (PTCL) that has returned or not responded to at least one previous treatment.
- You have not been treated with chidamide, lenalidomide, or bendamustine before.
- You have a tumor that can be measured on a scan (at least 1.5 cm).
- Your major organs (heart, liver, kidneys, lungs) and blood counts are working well enough.
- You are willing to use birth control if there is a chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment for peripheral T-cell lymphoma, a type of blood cancer. It may help patients who cannot tolerate standard chemotherapy or whose disease has come back.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a combination of four chemotherapy drugs for people with a type of lymphoma called peripheral T-cell lymphoma who have not had treatment before. The goal is to see if this combination can help control the cancer.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.